Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1

Related Experiment Video

Updated: Mar 27, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

7.2K

Sabin Llona-Minguez1, Andreas Höglund1, Sylvain A Jacques1

  • 1Division of Translational Medicine and Chemical Biology, Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

Journal of Medicinal Chemistry
|January 16, 2016
PubMed

Insights

Researchers developed novel dCTPase inhibitors to target cancer. These inhibitors enhance the effectiveness of cytidine analogues in leukemia cells, with Boronate 30 showing promise for further in vivo studies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • The enzyme dCTPase pyrophosphatase 1 (dCTPase) regulates intracellular nucleotide pools by degrading nucleotide triphosphates (dNTPs).
  • Elevated dCTPase expression is observed in various carcinomas, correlating with cancer cell stemness and potentially contributing to therapeutic resistance.
  • Targeting dCTPase presents a potential strategy for cancer therapy by modulating nucleotide metabolism.

Purpose of the Study:

  • To develop and characterize the first potent and selective inhibitors of dCTPase pyrophosphatase 1.
  • To evaluate the synergistic cytotoxic effects of these inhibitors in combination with cytidine analogues in leukemia cells.
  • To assess the in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) properties of a lead inhibitor candidate for potential in vivo application.

Main Methods:

  • Enzyme inhibition assays to determine potency and selectivity of novel dCTPase inhibitors.
  • Cell-based assays to evaluate the cytotoxic effects of dCTPase inhibitors alone and in combination with cytidine analogues in leukemia cell lines.
  • In vitro ADME profiling of lead compounds, including assessments of plasma and microsomal half-lives, aqueous solubility, cell permeability, and cytochrome P450 (CYP) inhibition.

Main Results:

  • Development of potent and selective dCTPase inhibitors, marking a significant advancement in targeting this enzyme.
  • Demonstration that these dCTPase inhibitors enhance the cytotoxic activity of cytidine analogues in leukemia cells, suggesting a therapeutic synergy.
  • Boronate 30 exhibited favorable in vitro ADME characteristics, including adequate half-lives, solubility, permeability, and low CYP inhibition, indicating its suitability for further preclinical development.

Conclusions:

  • Novel dCTPase inhibitors have been successfully developed, offering a new therapeutic avenue for cancers associated with high dCTPase expression.
  • The combination of dCTPase inhibitors with cytidine analogues shows enhanced cytotoxicity in leukemia, highlighting a promising strategy for overcoming resistance.
  • Boronate 30 possesses a promising preclinical profile, warranting further investigation in vivo for its potential as an anti-cancer agent.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
A High-Throughput Enzyme-Coupled Activity Assay to Probe Small Molecule Interaction with the dNTPase SAMHD108:17

A High-Throughput Enzyme-Coupled Activity Assay to Probe Small Molecule Interaction with the dNTPase SAMHD1

Published on: April 16, 2021

3.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
21
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.9K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
94.8K